Skip to main content

Table 1 Demographics of patients with BM

From: The impact of neurological performance and volumetrics on overall survival in brain metastasis in colorectal cancer: a retrospective single-center case series

  total CRC N = 25 colon cancer N = 11 rectal cancer N = 14
Number (%) mean (min-max) Number (%) mean (min-max) Number (%) mean (min-max)
patient characteristics
 gender, female 6 (24.00)   5 (45.45)   1 (7.14)  
 age at first diagnosis, yr   61.88 (30–81)   59.91 (30–81)   63.43 (51–78)
 age at first diagnosis, >  63 yr 10 (40.00)   4 (36.36)   6 (42.86)  
 body mass index, kg/cm2   26.1 (19.1–41.6)   26.3 (19.1–41.6)   25.9 (22.0–32.4)
 high blood pressure 13 (52.00)   7 (63.64)   6 (42.86)  
 alcohol consumption 2 (8.00)   0   2 (14.29)  
 smoking history 2 (8.00)   1 (9.09)   1 (7.14)  
 convulsion 6 (24.00)   1 (9.09)   5 (35.71)  
 cardiovascular disease 7 (28.00)   4 (36.36)   3 (21.43)  
 diabetes mellitus type II 4 (16.00)   4 (36.36)   0  
 second malignoma 2 (8.00)   1 (9.09)   1 (7.14)  
 chronic kidney injury 4 (16.00)   2 (18.18)   2 (14.29)  
 chronic obstructive pulmonic disease 4 (16.00)   2 (18.18)   2 (14.29)  
 cardiac stents 1 (4.00)   0   1 (7.14)  
 adipositas 4 (16.00)   2 (18.18)   2 (14.29)  
colorectal cancer
 UICC stage n/a 2 (8.00)   0   2 (14.29)  
I 3 (12.00)   1 (9.09)   2 (14.29)  
II 1 (4.00)   1 (9.09)   0  
III 10 (40.00)   6 (54.55)   4 (28.57)  
IV 9 (36.00)   3 (27.27)   6 (42.86)  
 Grading n/a 2 (8.00)   1 (9.09)   1 (7.14)  
G1 9 (36.00)   6 (54.55)   3 (21.43)  
G2 8 (32.00)   3 (27.27)   5 (35.71)  
G3 6 (24.00)   1 (9.09)   5 (35.71)  
 pulmonary metastasis 18 (72.00)   7 (63.64)   11 (78.57)  
 time from first diagnosis to pulmonary metastasis, mo   33.44 (0–103)   37.43 (0–82)   30.91 (0–703)
 liver metastasis 15 (60.00)   8 (72.73)   7 (50.00)  
 time from first diagnosis to liver metastasis, mo   19.27 (0–98)   30.29 (0–98)   9.63 (0–40)
 other systemic metastasis (without brain) 9 (36.00)   3 (27.27)   6 (42.86)  
 number chemotherapeutic drugs   3.08 (0–8)   3.64 (0–8)   2.64 (0–7)
 systemic chemotherapy w/o 2 (8.00)   0   2 (14.29)  
adjuvant 14 (56.00)   11 (100.00)   3 (21.43)  
neoadjuvant + adjuvant 9 (36.00)   0   9 (64.29)  
 systemic radiation therapy w/o 14 (56.00)   8 (72.73)   6 (42.86)  
neoadjuvant 4 (16.00)   0   4 (28.57)  
adjuvant 7 (28.00)   3 (27.27)   4 (28.57)  
brain metastasis
 age at diagnosis of BM, yr   65.80 (36–82)   64.27 (36–82)   67.00 (51–78)
 time from first diagnosis to BM, mo   47.16 (0–102)   52.91 (5–95)   42.64 (0–102)
 number of BMs 1 14 (56.00)   9 (81.82)   5 (35.71)  
2 3 (12.00)   0   3 (21.43)  
3 6 (24.00)   1 (9.09)   5 (35.71)  
> 3 2 (8.00)   1 (9.09)   1 (7.14)  
 localization of BM cerebral 9 (36.00)   6 (54.55)   3 (21.43)  
cerebellar 6 (24.00)   3 (27.27)   3 (21.43)  
both 10 (40.00)   2 (18.18)   8 (57.14)  
 symptoms of BM incidental finding 4 (16.00)   3 (27.27)   1 (7.14)  
unspecific CNS 3 (12.00)   3 (27.27)   0  
specific CNS 18 (72.00)   5 (45.45)   13 (92.86)  
 radiation therapy, brain 17 (68.00)   7 (63.64)   10 (71.43)  
 radiation therapy, modality stereotactic 11 (64.71)   5 (71.43)   6 (60.00)  
whole brain 6 (35.29)   2 (28.57)   4 (40.00)  
 radiation dose, Gy   38.31 (25–71)   33.50 (25–45)   41.20 (30–71)
surgery
 localization surgery cerebral 11 (45.83)   6 (54.55)   5 (38.46)  
cerebellar 13 (54.17)   5 (45.45)   8 (61.54)  
 cross total resection 13 (54.17)   8 (72.73)   5 (38.46)  
 age at death, yr   66.20 (37–81)   62.56 (37–81)   69.18 (51–79)
 time from first diagnosis to death, mo   51.75 (5–104)   56.44 (9–704)   47.91 (5–95)
 time from BM to death, mo   4.90 (0–18)   6 (0–18)   4 (0–9)
 time from BM to death, mo [median]   3.00 (0–18)   3 (0–18)   2 (0–9)
 six-month survival, mo 8 (40.00)   3 (33.33)   5 (45.45)  
 one-year survival, mo 2 (10.00)   2 (22.22)   0  
  1. BM brain metastasis, CI confidence interval, CRC colorectal cancer, CNS central nervous system, G grading, Gy Gray, HR Hazard ratio, KPS Karnofsky performance status, Mo months, MRC-NPS Medical Research Council Neurological Performance Ccore, N number, n/a not applicable, OS Overall survival, UICC Union for International Cancer Control, Yr years, w/o without